SARA (SARS-CoV-2 and Acetylsalicylic acid)
Efficacy of low dose acetylsalicylic acid in preventing adverse maternal and perinatal outcomes in SARS-CoV-2 infected pregnant women
- Duration
- 01/01/2023 - 31/12/2025
- Coordinator
- Clara Menéndez
- Funded by
- FIS-Instituto de Salud Carlos III
SARS-CoV-2 infection in pregnancy is associated with an increased risk of adverse maternal and perinatal outcomes. One explanation is that the infection might increase the existing pregnancy-associated prothrombotic status, leading to a higher risk of placental and vascular complications.
Administration of low-dose acetylsalicylic acid (LDASA) has shown to improve maternal and perinatal outcomes in women at high-risk of endothelial and placental complications. However, there are no data on the effect of LDASA in preventing complications in SARS-CoV-2- infected pregnant women.
Objective
To reduce SARS-CoV-2- related complications in a highly vulnerable group to the infection, we will carry out this randomized, double-blind, placebo-controlled multicentre trial in 400 SARS-CoV-2-infected pregnant women.
The study main objective is to evaluate the efficacy and safety of LDASA administered up to 36 weeks of gestation in SARS-CoV-2-infected pregnant women in reducing the incidence of adverse maternal and perinatal outcomes.
Pregnant women tested positive up to 32 weeks of gestation with a SARS-CoV-2 rapid antigen or PCR test and agreeing to participate, will be randomised 1:1 to receive daily LDASA (125 mg) or placebo up to 36 weeks of gestation and be followed-up until delivery.
Total Funding
153,670 €
Our Team
Coordinator
-
Clara Menéndez Santos
ISGlobal Team
-
Linda Stoeger Research Assistant -
Candelaria Serrano Clinical Trial Manager
Other projects
See Past ProjectsCaDMIA-plus
Continued validation of the minimally invasive autopsy for the investigation of the causes of death in infants, and establishment of a research and training center to study causes of death
MAMAH
Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women
ICARIA
Improving Care through Azithromycin Research for Infants in Africa
MIBio
Identification of Prematurity and Pre-Eclampsia as Causes of Mortality
MULTIPLY
MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention
MA-CoV
Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations
IPERVAC-SL
Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone
RESPIRE
Respiratory syncytial virus (RSV) in African pregnant women and children
VITAL
Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance
HIV drug resistance (HIVDR)
Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique
Evaluación de la eficacia del ácido acetilsalicílico a dosis bajas en la prevención de los efectos maternos y perinatales adversos en mujeres embarazadas infectadas por el SARS-CoV-2
PROTECT
PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa
